NEW YORK, Sept. 19 – Orchid Biosciences has received approval from the American Society of Histocompatibility and Immunogenetics to conduct human leukocyte antigen (HLA) testing using Luminex’ LabMap platform, Orchid said on Wednesday.
The company is the first to be certified to perform the testing with the LabMap platform, a bead-based system for DNA analysis.
Orchid plans to use the HLA testing to determine the potential for tissue or organ compatibility in single-sample testing and donor recruitment drives. The platform may also help determine whether a patient can accept donations of certain types of stem cells.
The LabMap system should reduce the time required to perform the testing, Orchid said in a statement. “Typically, customers have to wait at least a week to receive the results of molecular-based HLA testing,” Keith Brown, vice president and general manager of Orchid’s GeneScreen business unit, said in the statement. “Orchid’s adaptation of the Luminex platform for DNA-based HLA testing enables us to reduce the turnaround for HLA-DR testing to just several days and to improve the cost effectiveness of the testing process.”
Orchid’s GeneScreen business was approved in 1992 to perform HLA typing services using standard microbiology procedures. Receiving certification from the American Society of Histocompatibility and Immunogenetics requires standard test management and methodologies, quality control, assurance, proficiency testing, personnel qualifications, training and assessment, accreditation, and routine inspections, the company said.